Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORED
  • Sponsors Lexicon Pharmaceuticals; Sanofi

    • Most Recent Events

    • 02 May 2024 According to a Lexicon Pharmaceuticals media release, Sotagliflozin and kidney outcomes, kidney function, and albuminuria in T2DM and CKD: a secondary analysis of the SCORED Trial presented in the American Society of Nephrology (ASN) in January 2024, International Conference on Advanced Technologies & Treatments for Diabetes in March 2024 and American College of Cardiology in April 2024.
    • 08 Apr 2024 Results assessing whether Sotagliflozin Reduces Stroke Outcomes in Patients with Diabetes and Chronic Kidney Disease, presented at the 73rd Annual Scientific Session of the American College of Cardiology
    • 25 Mar 2024 According to a Lexicon Pharmaceuticals media release, four data including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease (CKD) from this study will be presented at the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top